← Leaderboards
Nicholas L Smith
University Of Washington
$14,759,772
Attributed
$23,935,943
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,935,943 · 9
By mechanism
R01$20,411,714 · 6
R33$1,967,631 · 1
R61$1,372,686 · 1
R21$183,912 · 1
Top collaborators
- Charles J Lowenstein9 shared
- Alisa S Wolberg9 shared
- Alanna C Morrison6 shared
- Nathan D Pankratz4 shared
- Paul Stefan De Vries3 shared
- Mariza De Andrade2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Gail Pairitz Jarvik$65,999,335
Others in their field
Top investigators on “Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$59,264,235
- John H Griffin · Scripps Research Institute$29,245,116
- David J. Pinsky · University Of Michigan At Ann Arbor$29,054,903
- Bruce Furie · Beth Israel Deaconess Medical Center$28,093,838
- Denisa D Wagner · Boston Children'S Hospital$24,247,974
- Satya P. Kunapuli · Temple University$22,403,131
Research focus
ThrombosisVariantVenous ThrombosisEventCoagulation ProcessGenesResourcesGeneticProteinsPlasmaPhenotypePulmonary EmbolismHemostatic AgentsDeep Vein ThrombosisBiologicalPathway InteractionsBaseGenomicsHemostatic FunctionVenous ThromboembolismCandidate Disease GeneBloodGenetic VariantWoman
Grant awards (38)
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$704,932
R01 · FY2025 · HL
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$640,459
R01 · FY2024 · HL
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$625,301
R01 · FY2024 · HL · contact PI
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$738,047
R01 · FY2023 · HL
Structural and Nucleotide Variation as Genomic Risks for Venous Thrombosis: TOPMED and INVENT Collaboration$720,705
R01 · FY2023 · HL · contact PI
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$636,762
R01 · FY2023 · HL · contact PI
Structural and Nucleotide Variation as Genomic Risks for Venous Thrombosis: TOPMED and INVENT Collaboration$743,125
R01 · FY2022 · HL · contact PI
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$640,374
R01 · FY2022 · HL · contact PI
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$626,843
R33 · FY2022 · HL
Structural and Nucleotide Variation as Genomic Risks for Venous Thrombosis: TOPMED and INVENT Collaboration$743,125
R01 · FY2021 · HL · contact PI
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$667,852
R33 · FY2021 · HL
Genetic Discovery and Functional Validation to Identify Precursors of Clot Embolization in those with a Deep Vein Thrombosis$656,756
R01 · FY2021 · HL · contact PI
Structural and Nucleotide Variation as Genomic Risks for Venous Thrombosis: TOPMED and INVENT Collaboration$772,954
R01 · FY2020 · HL · contact PI
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$711,387
R01 · FY2020 · HL
Population genomic variation, functional biology, and the risk of venous thrombosis$708,902
R01 · FY2020 · HL · contact PI
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$672,936
R33 · FY2020 · HL
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$734,487
R01 · FY2019 · HL
Population genomic variation, functional biology, and the risk of venous thrombosis$710,830
R01 · FY2019 · HL · contact PI
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$672,507
R61 · FY2019 · HL
Analysis of Whole Genome Sequence and Hemostasis Phenotypes$759,227
R01 · FY2018 · HL
Population genomic variation, functional biology, and the risk of venous thrombosis$714,467
R01 · FY2018 · HL · contact PI
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biology$700,179
R61 · FY2018 · HL
Population genomic variation, functional biology, and the risk of venous thrombosis$736,908
R01 · FY2017 · HL · contact PI
The Association of Vasomotor Symptoms with Thrombosis in Postmenopausal Women$91,902
R21 · FY2015 · HL · contact PI
The Association of Vasomotor Symptoms with Thrombosis in Postmenopausal Women$92,010
R21 · FY2014 · HL · contact PI
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis$613,161
R01 · FY2012 · HL · contact PI
Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal women$601,823
R01 · FY2012 · HL · contact PI
Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal women$615,599
R01 · FY2011 · HL · contact PI
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis$576,315
R01 · FY2011 · HL · contact PI
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis$647,379
R01 · FY2010 · HL · contact PI
Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal women$620,021
R01 · FY2010 · HL · contact PI
Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal women$633,117
R01 · FY2009 · HL · contact PI
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis$560,154
R01 · FY2009 · HL · contact PI
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosis$521,498
R01 · FY2008 · HL · contact PI
Clotting genetic variant, hormones and venous thrombosis$567,323
R01 · FY2007 · HL · contact PI
Clotting genetic variant, hormones and venous thrombosis$580,150
R01 · FY2006 · HL · contact PI
Clotting genetic variant, hormones and venous thrombosis$583,584
R01 · FY2005 · HL
Clotting genetic variant, hormones and venous thrombosis$592,842
R01 · FY2004 · HL